

## PRESS RELEASE

---

### ProBioGen Co-Develops New Freedom™ ExpiCHO-S™ Cell Line Development Kit

Berlin, Germany – October 27, 2022

Following the success of the [Gibco™ Freedom™ CHO-S](#) Cell Line Development Kit, ProBioGen and [Thermo Fisher Scientific](#) have teamed up again to develop an even better platform: the [Gibco™ Freedom™ ExpiCHO-S™](#) Cell Line Development Kit. It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field. Applying its strong expertise in cell line and process development, ProBioGen has substantially contributed to the performance of the Freedom ExpiCHO-S Kit.

The new kit uses Thermo Fisher's ExpiCHO-S cell line and a new powerful media platform specifically developed for it. The kit is based on a novel set of ProBioGen vectors equipped with strong promoters, selection markers and protective elements providing expression stability. Together with a simple workflow optimized by ProBioGen, the kit provides short development time, reproducibly high titers (3-5 g/L) and high expression stability.

"Generating a stable and high performing cell line is the starting point for successful pharmaceutical development. The Gibco Freedom ExpiCHO-S Kit allows seamless transition from transient to stable production reproducing previously found product modifications. Moreover, the specific ProBioGen vector composition offers flexibility not only for antibodies but in particular for a variety of novel product formats", stated Dr. Volker Sandig, ProBioGen's Chief Scientific Officer.

The [Gibco Freedom ExpiCHO-S Kit](#) is sold by Thermo Fisher Scientific.

To find out more about ProBioGen and Thermo Fisher's collaboration on the new kit, and to get other ProBioGen updates, sign up for our [newsletter](#) to receive content including the Inside Bioprocessing podcast: 'Optimizing stable clone development to improve biopharmaceutical production'. Topics discussed in the podcast include the design and expression of plasmids; the expansion of desired clones for stable protein production; how to streamline this process; and the future of stable clone development.

#### About ProBioGen

[ProBioGen](#) is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.

Combining both state-of-the-art development services, based on ProBioGen's expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 25 years. At three locations in Berlin, nearly 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

ProBioGen's growth strategy includes strategic alliances like the one with Thermo Fisher Scientific and the expansion of the value chain through organic growth and potential acquisitions.

For more information about ProBioGen, follow us on [LinkedIn](#).

**ProBioGen Contact:**  
Dr. Gabriele Schneider  
Chief Business Officer  
[cdmo@probiogen.de](mailto:cdmo@probiogen.de)

**ProBioGen Press Contact:**  
Sarah Wandrey  
Corporate Communications  
[press@probiogen.de](mailto:press@probiogen.de)